Thursday, March 28, 2013

Atossa Genetics Gets $30M In PIPE

Seattle-based Atossa Genetics said Thursday that it has raised $30M more, in a stock purchase agreement with Aspire Capital. The publicly held firm, which is developing diagnostics for breast cancer, said Aspire paid $12.00 per share for $1M of its common stock, and has committed to an additional $29M of its stock over the next three years.